Clinical TrialMay 26, 2026, 09:02 AM
Corbus Pharma CRB-701 shows robust activity in OPSCC & cervical cancer
AI Summary
Corbus Pharmaceuticals announced updated Phase 1/2 clinical data for CRB-701, a Nectin-4 targeted ADC, demonstrating robust activity in second-line oropharyngeal squamous cell carcinoma (OPSCC) and cervical cancer. The data, to be presented at ASCO 2026, showed confirmed objective response rates of 42.9% in OPSCC and 34.4% in cervical cancer at the 3.6 mg/kg dose, with favorable safety and low discontinuation rates. The company also reported positive early weight loss data for CRB-913 in obesity and confirmed broad FDA alignment for registrational studies for CRB-701 in both cancer indications, with the OPSCC study expected to start in summer 2026.
Key Highlights
- CRB-701 achieved 42.9% confirmed ORR in 2L oropharyngeal squamous cell carcinoma (OPSCC) at 3.6 mg/kg.
- CRB-701 achieved 34.4% confirmed ORR in 2L cervical cancer at 3.6 mg/kg.
- Median Duration of Response was 6.3 months for OPSCC and 8.0 months for cervical cancer.
- CRB-701 demonstrated a favorable safety profile with treatment discontinuations below 3%.
- Registrational study (TEMPO-1) for CRB-701 in 2L OPSCC is on track to initiate in summer 2026.
- FDA alignment was reached for registrational studies in both 2L OPSCC and 2L cervical cancer.
- CRB-913 showed 2.9% average placebo-adjusted weight loss at day 14 in a Phase 1b obesity study.
Price Impact
More from CRBP